149 related articles for article (PubMed ID: 38640321)
21. A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.
Pi Y; Sun F; Zhang Z; Liu X; Lou G
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512088
[No Abstract] [Full Text] [Related]
22. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
23. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
24. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
25. Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer.
Ding B; Yan W; Shen S; Meng D; Chen X; Wang S; Shen Y
Cancer Control; 2023; 30():10732748231168756. PubMed ID: 37078136
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
[TBL] [Abstract][Full Text] [Related]
27. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
Fei H; Han X; Wang Y; Li S
J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
[TBL] [Abstract][Full Text] [Related]
28. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract][Full Text] [Related]
29. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer.
Li C; Yang L; Zhang Y; Hou Q; Wang S; Lu S; Tao Y; Hu W; Zhao L
Front Immunol; 2023; 14():1307588. PubMed ID: 38235137
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
31. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract][Full Text] [Related]
32. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
You Y; Yang Q
BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
[TBL] [Abstract][Full Text] [Related]
33. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
34. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
35. Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer.
Jiang H; Awuti G; Guo X
ACS Omega; 2023 Sep; 8(36):33017-33031. PubMed ID: 37720747
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
37. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
Zhu K; Ma J; Tian Y; Liu Q; Zhang J
BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
[TBL] [Abstract][Full Text] [Related]
38. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
39. Weighted Gene Co-expression Network Analysis Identifies a Cancer-Associated Fibroblast Signature for Predicting Prognosis and Therapeutic Responses in Gastric Cancer.
Zheng H; Liu H; Li H; Dou W; Wang X
Front Mol Biosci; 2021; 8():744677. PubMed ID: 34692770
[No Abstract] [Full Text] [Related]
40. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
Zheng J; Guo J; Zhu L; Zhou Y; Tong J
J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
